ClinicalTrials.Veeva

Menu

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection (ENDURANCE-2)

AbbVie logo

AbbVie

Status and phase

Completed
Phase 3

Conditions

Chronic Hepatitis C Virus (HCV) Infection

Treatments

Drug: ABT-493/ABT-530
Drug: Placebo for ABT-493/ABT-530

Study type

Interventional

Funder types

Industry

Identifiers

NCT02640482
2015-002348-14 (EudraCT Number)
M15-464

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and efficacy of ABT-493/ABT-530 in adults with genotype 2 chronic hepatitis C virus (HCV) infection.

Enrollment

304 patients

Sex

All

Ages

18 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Screening laboratory result indicating hepatitis C virus (HCV) Genotype-2 (GT2) infection.
  • Chronic HCV infection.
  • Subject must be HCV treatment-naïve (subject had never received a single dose of any approved or investigational regimen) or had failed prior interferon (IFN) or pegylated-interferon (pegIFN) ± ribavirin (RBV) or sofosbuvir (SOF) + RBV ± pegIFN therapy.
  • Subject must be non-cirrhotic.

Exclusion criteria

  • History of severe, life-threatening or other significant sensitivity to any excipient of the study drugs.
  • Female who is pregnant, planning to become pregnant during the study, or breastfeeding; or male whose partner is pregnant or planning to become pregnant during the study.
  • Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse that could preclude adherence to the protocol in the opinion of the investigator.
  • Positive test result at Screening for hepatitis B surface antigen (HBsAg) or anti-human immunodeficiency virus antibody (HIV Ab).
  • HCV genotype performed during screening indicating coinfection with more than 1 HCV genotype.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

304 participants in 3 patient groups

Arm A DB Active Drug
Experimental group
Description:
ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks (double-blind \[DB\] treatment period)
Treatment:
Drug: ABT-493/ABT-530
Arm B DB Placebo
Experimental group
Description:
Placebo for ABT-493/ABT-530 QD for 12 weeks (DB treatment period)
Treatment:
Drug: Placebo for ABT-493/ABT-530
Arm B OL Active Drug
Experimental group
Description:
ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks (open-label \[OL\] treatment period)
Treatment:
Drug: ABT-493/ABT-530

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems